<DOC>
	<DOCNO>NCT00189306</DOCNO>
	<brief_summary>An open-label study evaluate safety ability Imiquimod 5 % cream , apply topically , clear superficial basal cell carcinoma keep clear 5 year follow-up .</brief_summary>
	<brief_title>Open-label Study Evaluate Clearance Superficial Basal Cell Carcinoma After Use Imiquimod 5 % Cream</brief_title>
	<detailed_description>Evaluate long-term sustained clearance rate , define proportion subject clinically clear basal cell carcinoma ( BCC ) treat superficial BCC ( sBCC ) target tumor site 12-week posttreatment visit remain clear 5 year follow-up period .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Have least 1 previously untreated superficial basal cell carcinoma tumor Minimum tumor size 0.5 cm2 maximum diameter 2.0 cm Evidence clinically significant , unstable medical condition Can recent use topical steroid retinoids treatment area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Superficial Basal Cell Carcinoma</keyword>
	<keyword>Aldara</keyword>
</DOC>